ALZHEIMER'S DISEASE (AD)
2 is a progressive neurodegenerative disorder characterized by irreversible cognitive and physical deterioration. It is a major cause of death and a growing public health problem as life expectancy in the general population increases. The first case report of Alzheimer's disease was published in 1907 by Alois Alzheimer (1) . It described the autopsy findings for a woman who died at age 55 with progressive dementia and in whom newly available silver stains revealed the presence of abnormal nerve cells containing tangles of fibers (neurofibrillary tangles) and neuritic plaques in the cerebral cortex.
Much work has been done since then to identify the etiology and pathophysiological mechanisms that lead to the premature dysfunction and death of the neurons that characterize Alzheimer's disease. A molecular characterization of structures that constitute the neuropathological lesions typical of AD, the neuritic plaques and neurofibrillary tangles, are one approach to that question. Extracellular senile plaques in their classical form represent a compacted amyloid deposit consisting mainly of b-amyloid (or Ab), a fragment of a larger protein defined as amyloid precursor protein (APP) (2, 3) that is expressed in all mammalian tissues except in nonnucleated red blood cells (4) . Neurofibrillary tangles (NFT) represent intraneuronal bundles of paired helical filaments (PHF), which consist mainly of the microtubule-associated tau protein in an abnormally phosphorylated form and ubiquitin (5, 6) . The reason why this abnormal accumulation of amyloid and PHF occurs in the AD brain is not yet clear.
Pathophysiological studies and diagnosis of the disease rely in part on the use of brain tissue from diseased patients. In particular, confirmation of AD diagnosis is only possible postmortem by neuropathological analysis, despite the lack of complete specificity of central markers such as amyloid plaques and NFT. Senile plaques and NFT are not unequivocal markers of Alzheimer's disease. In fact, amyloid plaques can be observed in the brain of normal aged donors (7) . NFT can also be detected in the brain of other neurodegenerative disorders such as Pick's disease, progressive supranuclear palsy, and corticobasal degeneration (8) .
Accordingly, there is an active search to identify accessible tissues or body fluids that are suitable for exploring pathophysiological hypotheses and that provide a biological marker with which to confirm diagnoses. Although this latter goal still eludes the efforts of the investigators, some relevant data have been obtained that contribute to the characterization of working pathophysiological hypotheses, such as in the case of amyloid precursor metabolism or oxidative metabolism dysfunction.
THE USE OF PERIPHERAL TISSUES: RATIONALE AND METHODOLOGICAL CONSTRAINTS
To identify the cellular and molecular abnormalities that cause the characteristic neuropathological lesions of AD, autopsied brains and extraneural tissues have been used. The use of peripheral cells is based on the hypothesis that Alzheimer's disease might be a systemic disease that affects several tissues in the body. The specific brain damage could be the expression of a greater sensitivity to injury in postmitotic cells of the brain. Furthermore, a potential genetic defect underlying the disease may be manifest in several body tissues that express the gene involved.
Peripheral tissues suitable for exploring pathophysiological hypotheses and possibly for providing a useful biological marker for diagnosis of AD include skin fibroblasts, platelets, lymphocytes, as well as body fluids such as plasma or cerebrospinal fluid (CSF). Among these tissues, cultured skin fibroblasts have been used successfully to elucidate the molecular and biochemical bases of many inborn errors of metabolism that cause neurological disease, i.e., Refsum's disease (9) and Lesch-Nyhan disease (10). Moreover, fibroblasts are an appropriate model for studies of those genetic diseases of the nervous system with late clinical onset, including familial Alzheimer' s disease, because they can be easily cultured and stored and contain the complete genomic information of the organism.
As always when studying the effect of a pathology on a given tissue, the choice of appropriate controls and the problem of distinguishing those changes that are due to the disease from effects related to other aspects of the patients, such as nutritional status and drug treatments, are key issues. This problem is most important for cells such as platelets and lymphocytes, which are influenced more by the patients' condition, but nutritional and drug effects are enormously diluted in cultured fibroblasts. When using cultured skin fibroblasts, some technical variables should also be considered. Growth properties and in vitro aging of AD and control fibroblast cultures do not differ under standard conditions (11) (12) (13) (14) , although this topic is still controversial. Since growth properties and biological age in culture can have profound effects on the properties of cells cultured from skin, including the expression of genes (which could be related to AD) (15) , reproducible and interpretable results with the AD fibroblasts model require attention to the replicability of culture conditions including, but not limited to, matching AD and control cells for age, sex of the donors, and biological age in culture, i.e., cumulative population doubling level and percentage of life span completed (16) . Different growth conditions, aging of cultures in vitro, and state of confluency of the cells at the time of the experiment may account for discrepancies between data from different laboratories. Only abnormalities replicated in larger series across different laboratories or characterizing subgroups of AD patients are likely to be of relevance (17) in diagnosing Alzheimer's disease. This diagnosis indeed appears to be the major challenge posed by AD in its sporadic lateonset form, which still represents the vast majority of all cases.
On the other hand, data obtained using fibroblasts from individuals with known gene defects, although representing only a small proportion of all AD cases, could be very informative about the cellular pathophysiology of Alzheimer's disease. Recent advances in understanding the genetics of AD allow identification of families bearing mutations in APP, presenilin 1 (PS1), or presenilin 2 (PS2) genes coded on chromosomes 21, 14 and 1, respectively (18) . Fibroblast lines from familial AD patients can now be classified according to the specific gene defect to see whether a particular genetic abnormality alters cellular function in a unique manner ( Table 1) .
Peripheral cells are therefore useful in identifying and testing hypotheses on the primary pathophysiological mechanisms leading to Alzheimer's disease and for avoiding variables derived from a postmortem state. On the other hand, peripheral cells cannot be used to answer other clinically relevant questions that require an intact organism. Low or absent expression of neuronal proteins by peripheral cells cultured under standard conditions is an important limiting factor. In the study of AD and other neurological diseases, peripheral cells are indeed an adjunct for studies of the brain and other clinically affected tissues, providing the tools to study in vitro the dynamic alteration of metabolic processes that neuropathological examination indicates might be targets of the disease. An example is given by the studies of protein kinase C (PKC) (detailed below), whose altered levels and activity in AD brain have also been consistently found in peripheral tissues. In turn, the use of fibroblasts has uncovered the correlation between altered PKC and APP metabolism. The same arguments can be applied to studies of cAMP production, which was found to be altered both in the brain and in fibroblasts of AD patients, and where the use of the peripheral tissue allowed a more detailed pharmacological dissection of the system and yielded important indications on the putative dysfunctional sites in AD.
PERIPHERAL CELLS

Alterations of transduction systems in AD peripheral cells
Studies of the PKC system ( Fig. 1, and Fig. 2 However, the main differences were in PKC functional regulation instead of PKC basal activity. In fact, the observed reduction in NK-PKC activity in healthy elders after long-term exposure to stimulating cytokines (i.e., interleukin 2, IL-2; interferon b, IFN-b) might be ascribed to a process of down-regulation of the PKC tending to reduce cytotoxicity after previous activation. In AD patients, a lack of PKC down-regulation during IL-2 and IFN-b exposure suggests a potentiated excitatory response of NK cells in these patients. An enhanced cytotoxic response to IL-2 and IFN-b was observed in AD patients, whereas healthy elders had cytokine-induced NK cytotoxicity similar to that of healthy young subjects. This alteration seems to be specific for AD, since previous data (30, 31) reported normal NK activity and regulation in patients suffering from vascular dementia (clinically diagnosed).
Other transduction systems have also been investigated. A reduction in b-adrenergic-stimulated cAMP increase (32) has been demonstrated. Diminished adenylate cyclase activity did not underlie these abnormalities, since direct stimulation of adenylate cyclase by forskolin elevated cAMP production equally in Alzheimer and control fibroblasts. Extensive studies using pharmacological probes indicated Fig. 2 and text for more details). Alterations have been described in the coupling of G-protein-associated receptors to their effector as well as in phosphorylating enzymes and ionic homeostasis. 1) The coupling of b-adrenergic receptors to adenylate cyclase was found defective; 2) an increase in IP 3 production in response to bradykinin appears to be linked to an increase in receptor number in fibroblasts of AD patients; 3) protein kinase C activity has been consistently found to be reduced in AD fibroblasts, and a decreased activity and translocation of the kinase have also been demonstrated in the brain; 4) calcium homeostasis undergoes complex alterations involving calcium entry and calcium handling by the cell leading to dysregulation of its cytosolic concentrations in response to various stimuli (see text for details); 5) in fibroblasts, some of the abnormal calcium response may depend on the dysfunction of a particular K / channel. Abbreviations: AC: adenylate cyclase; bAR: beta-adrenergic receptor; BKR: bradykinin receptor; CaBP: calcium bindign proteins; DAG: diacylglycerol; G: G-protein; IP 3 : inositol tris-phosphate; IP 3 R: inositol tris-phosphate receptor; PIP 2 : phosphatidylinositol bis-phosphate; PKA: protein kinase A; PKC: protein kinase C; PLC: phospholipase C; RACK: receptor for activated C kinase.
an abnormality in the coupling of G-proteins to the b-adrenergic receptor in the cultured AD cells. Furthermore, the phosphoinositide cascade was investigated in cultured skin fibroblasts from AD and control subjects. Although basal inositol-(1,4,5)-trisphosphate (IP 3 ) levels are similar in AD and control cells, the bradykin (BK) -stimulated increase in IP 3 levels was much greater in AD fibroblasts than in controls. Elevated IP 3 production in response to BK in AD fibroblasts is positively correlated with an increase in receptor number (33). The changes in bradykinin receptors and subsequent increased sensitivity to bradykinin in AD fibroblasts are unrelated to PKC (34). In fact, whereas acute activation of PKC with phorbol esters rapidly reduces the number of bradykinin receptors in normal cells, the prolonged down-regulation of PKC is not paralleled by a compensatory increase in BK receptors.
When considered together, studies of the transduction systems (summarized in Fig. 1 ) suggest that any pharmacological intervention with direct or indirect receptor agonists aimed at ameliorating the impaired cerebral functions of AD may produce only modest results due to ineffective transduction of the agonist-promoted message, since some of these systems are impaired in AD patients.
Alterations in amyloid precursor protein metabolism
APP has the structure of an integral membrane protein and is composed of a large extracellular domain at the amino terminal, followed by a transmembrane domain and a 47 amino acid residue intracellular domain at the carboxyl terminus. The amyloidogenic sequence (Ab) begins near the end of the extracellular domain and extends approximately halfway through the transmembrane portion (35). APP follows the normal constitutive secretory pathway and is cleaved by a so-called a secretase that releases the ectodomain (soluble APP, or sAPP) into the extracellular space (see cleavage occurs within the Ab sequence, thereby preventing the formation of amyloidogenic fragments (36). On the other hand, there is evidence that Ab can be formed and secreted as a physiological product of cell metabolism (37). The routing of APP into these two pathways may be directed by protein phosphorylation. Several reports in the literature demonstrate that PKC activation with phorbol esters not only increases sAPP secretion via the nonamyloidogenic pathway (38-41), but can also decrease bamyloid secretion (42-44). In particular, experiments on transfected cells suggest that PKC-a was involved in APP secretion (45).
By using skin fibroblasts from sporadic AD patients and control subjects, researchers demonstrated that the defective PKC activity (see above) is followed by a reduced basal sAPP secretion from AD cells. This indicates a constitutive deficiency in APP processing despite a lack of differences in APP expression in AD and non-AD cells in sporadic cases (46; S. Govoni, unpublished data). Furthermore, whereas high concentrations of phorbol ester (ú75 nM) produced maximal, but equivalent, release of APP from both groups of cells, reduced sAPP release from AD cells was observed at low phorbol ester concentrations (õ18 nM), with an EC 50 in AD fibroblasts twofold higher than in control fibroblasts. The ratio between the EC 50 values of AD and non-AD cells mirrors the ratio found for the K d of labeled phorbol ester binding in the same cell lines (25, 26). Moreover, this defective regulation of amyloid precursor protein secretion might be correlated with a specific defect in PKC-a (26). The data described were the first report of an alteration in APP secretion in fibroblasts derived from sporadic Alzheimer's disease patients, and led to the hypothesis that the altered APP metabolism that may underlie the pathology can be observed in peripheral cells as well as in the brain of sporadic AD patients.
This concept was even more strongly supported by data obtained using cells derived from patients with familial Alzheimer's disease (FAD). Recent findings demonstrated an alteration in APP metabolism, with a threefold increase in Ab secretion from skin fibroblasts derived from familial AD patients of the Swedish kindred (47) ( Table 1 2) a putative role of presenilins is that of regulating the trafficking of APP in the constitutive secretory pathway leading to full maturation of the holoprotein in the trans Golgi network. From this compartment, APP can follow two alternative routes to the cell surface. Via packaging in secretory vesicles (3), APP can travel to the plasma membrane (4); during this passage, APP can be cleaved either in the vesicle or at the plasma membrane by a secretase and then release (5) soluble sAPP into the extracellular compartment. This route is alternative to the compartmentalization of APP into acidic organelles (6), distinct from the lysosomes where Ab is formed via b and g secretases and then released into the extracellular milieu. The routing of APP into these two pathways is under the control of protein phosphorylation, in particular by PKC, a mechanism that is defective in sporadic AD fibroblasts (see text). The mechanism is presently unknown, but presenilins are also presumed to play a role in the regulation of these pathways. Finally, the endosomal/lysosomal pathway (7) is called into action for degradation of the carboxyl-terminal fragment left over by secretase processing (5) and for the degradation of full-length APP molecules recycling from the cell surface or directly from the biosynthetic pathway through the Golgi cisternae.
carboxyl-terminal, potentially amyloidogenic fragment.
Even if these data support the constitutive role of b-amyloid in Alzheimer's disease, a word of caution should be sounded. No direct studies have been performed to determine whether there is any systematic biological difference between the symptomatic and presymptomatic patients apart from the presence of the signs and symptoms of illness. A comparison of data obtained using tissues derived from presymptomatic patients before the age of onset of the disease for the investigated family and after that age on both symptomatic cases and escapees is needed before making firm conclusions.
The view that fibroblasts can be used to effectively monitor pathology-induced defects of APP metabolism also emerges from experiments on Down's patients. Patients with trisomy 21 (Down's syndrome, DS) virtually always develop dementia of the Alzheimer's type after the fourth decade of life and show a histopathological phenotype indistinguishable from AD, presumably on the basis of increased APP gene dosage and transcription. Querfurth et al. (46) demonstrated an increased APP mRNA level in DS fibroblasts similar to that observed in FAD. They also demonstrated an increase in Ab secretion in fibroblasts from DS and FAD-affected subjects as compared to control cells. However, caution must be observed when using information obtained from Down's patients to model biochemical defects in Alzheimer's disease. In fact, data obtained from skin fibroblasts of DS subjects (51) show a completely different pattern of sAPP secretion with respect to sporadic AD cells under basal conditions and after PKC activation with phorbol esters. The sAPP basal release from DS fibroblasts is twofold that of age-matched / 381c 0002 Mp 23 Tuesday Nov 25 11:34 AM LP-FASEB 0002 control cells. Moreover, stimulated APP release is already maximal at low phorbol ester concentrations (9 nM), and the peak response is lower on a percentage basis than in control fibroblasts because of higher basal release. Thus, in DS fibroblasts, PKCsensitive secretion can be stimulated only modestly, indicating a saturation of this pathway due to the higher APP content of DS cells when compared to control and AD fibroblasts. These results also indicate that the PKC-sensitive mechanisms that control APP release might be saturated and might depend on the level of APP expression. These observation stress the importance of evaluating APP expression after pharmacological treatments with a potential effect on APP secretion, since changes in this parameter may reset the system and affect the pool of the precursor available for secretion under basal or stimulated conditions. ] i (54-57). Alterations in calcium homeostasis have also been found in peripheral cells (Fig. 2, step A) . The first study utilizing fibroblasts from AD patients revealed that calcium uptake declines (58) . Total membranebound calcium increases in fibroblasts in normal aging and is elevated even further in those with Alzheimer's disease (59) . Other reports suggest that cytosolic free calcium decreases; however, this has not been replicated (60, 61) . Cytosolic free calcium concentration is increased in platelets (62) and lymphocytes derived from AD patients (63), but not in lymphoblasts (64) . In addition, freshly prepared human lymphocytes showed elevated mitogen-induced calcium responses after exposure to b-amyloid (65) (66) (67) . A diminished response of cytosolic free calcium to drugs such as bradykinin has been found in AD fibroblasts by some (61, 68, 69) but not all groups (70) (71) (72) (73) . The discrepancy may be due to the concentration of bradykinin used; Huang et al. (70) and Ito et al. (73) have observed an exaggerated response to low (nanomolar concentrations) BK concentrations by using AD fibroblasts.
Altered internal calcium stores have been demonstrated by different treatments in AD fibroblasts.
Bombesin elevates cytosolic free calcium more in cells from AD patients than in controls (73) (74) . Another study that demonstrated altered internal calcium pools in Alzheimer fibroblasts revealed that mitochondria from AD fibroblasts had decreased calcium uptake (75) .
A greatly diminished response of cytosolic free calcium to high concentrations of the potassium channel blocker tetraethylammomium (TEA) also suggests that regulation of calcium entry is abnormal in AD fibroblasts. Patch clamp studies indicate that this abnormal calcium response reflects the functional absence of a particular K / channel (76). The apparent lack of replicability with fibroblasts has been particularly striking for the study of calcium homeostasis. Many laboratories are equipped to measure calcium, but methodological variations are great. In addition, controlling all the variables of tissue culture (presence or absence of antibiotics, synchrony of the cell cycle, cumulative population doubling level at the time of the experiments, interval between seeding and when the measurement is made, seeding density) is extremely difficult. In fact, the reduced resting calcium and the diminished response to bradykinin previously observed in AD fibroblasts (60, 68) have been difficult to replicate (70, 73) . The inability to repeat these findings may have been partially related to the cell phase in which the various studies were performed. Recent results replicated the decreased response to bradykinin, vasopressin, or serum in familial AD cells if the cells were studied in S phase (69) . No AD/control difference occurs after bradykinin stimulation when the cells are in G2 or M phase. Similarly, if cells are studied 7 days after plating, 40-60% decreases are apparent in the AD fibroblasts (69) . Another measure of calcium homeostasis where the method of measurement accounts for the apparent discrepancies is where the potassium channel blocker TEA elevates cytosolic free calcium in controls, but not AD fibroblasts. In the original report, addition of TEA distinguished AD cell lines from controls (76) . However, a recent report did not find this measure to discriminate between AD and controls (77) . Methodological differences may account for the discrepancies. The original study used microscopic imaging to examine individual cells and calculate the percent of responding cells (76) . However, experiments from Matsuyama et al. (77) averaged microscopic fields that contained many cells, which severely limits resolution and sensitivity.
Experiments on the bradykinin-induced IP 3 response provide an example in which treatment of the cells accounts for the lack of replicability between studies. The initial study found no differences in IP 3 formation in control and AD cells when IP 3 (33) . Subsequent experiments showed that IP 3 formation was enhanced in AD cells regardless of the method of measurement, as long as the treatment did not include prolonged serum deprivation (33). These discrepancies (also reviewed in ref 78) should not be viewed as a reason to dismiss this approach. Research on fibroblasts has progressed to a stage that elucidating the underlying mechanistic basis of any of these discrepancies is possible if adequate attention is paid to the details of experimental techniques used.
Alterations in oxidative metabolism in AD peripheral cells
Increased lactate production and altered glucose utilization occur (59, 79, 80) in AD fibroblasts. The activities of key mitchondrial enzymes such as a-ketoglutarate dehydrogenase are diminished either slightly (81) or by as much as 40% (82) in Alzheimer fibroblasts. This last result has been confirmed in an independent series of experiments showing inherent defect of the a-ketoglutarate dehydrogenase complex (83) . Glutamine oxidation also declines (59, 79, 80) in AD cells, although not always (84) . Furthermore, reduced cytochrome c oxidase (CO) activity was demonstrated in platelets derived from AD patients (85) and also in AD fibroblasts from our bank (Govoni et al., unpublished results). Recently published data (86) describe genetic defects in the mitochondrial DNA coding for CO subunits CO1 and CO2. However, these results await independent confirmation in a different series of patients. These results are all consistent with the hypothesis that abnormal oxidation in AD brain is not just secondary to neurodegeneration, but the hypothesis needs to be investigated further. Finally, abnormalities in cerebral metabolism of oxygen and glucose can be expected to interact synergistically with cerebrovascular factors in causing brain damage in AD.
Use of peripheral cells as an aid in diagnosing disease
Peripheral cells-and in particular cultured skin fibroblasts from AD patients-might provide a useful aid in AD diagnosis. Today, the criteria needed for a conclusive diagnosis of AD include clinical criteria in association with histopathologic evidence obtained from a biopsy or autopsy. Thus, the use of peripheral cells as a diagnostic tool, either to predict or at least to confirm the diagnosis, may be of great importance. None of the alterations described in peripheral cells can now be used as a diagnostic tool if considered alone. One possible approach to achieve this goal is to combine more than one set of data and thereby provide a profile for AD cells distinguishable from that of controls.
The first attempt in this direction was made by Hirashima et al. (87) . Previous findings by the same authors demonstrated the absence of a specific potassium channel and of TEA-induced calcium increase in AD fibroblasts (76) . The stimulation of calcium release from intracellular stores in response to bombesin or low BK concentrations was greatly enhanced in AD fibroblasts compared with cells from control donors (73) . On the basis of these results, Hirashima (87) introduced a scoring system that integrated altered and normal responses to low BK concentrations, bombesin, and TEA stimulation of intracellular calcium elevation in AD vs. control fibroblasts. This scoring system also takes into account the degree of responsiveness and/or unresponsiveness of each particular cell line. It generated an index distinguishing AD patients from controls with both high specificity and sensitivity (87) . The authors have also examined many non-Alzheimer's dementia controls and still found complete specificity. These results indicate that by taking the overall profile of responses into account, it is possible to enhance the diagnostic value of these cellular alterations. Furthermore, the diagnostic measurements obtained in fibroblasts appear to be closely correlated for two populations of patients living in distant geographic areas, since cells used for the study described were obtained from Coriell Cell Repository (Camden, N.J.) and a fibroblast bank established in Brescia, Italy (Project Ministry of Health #500.7 AG/4.8455/ Regione Lombardia). Moreover, specificity and sensitivity of the assay should be established by including patients bearing different kinds of neurological diseases in order to determine the ability of the marker to distinguish AD from normal aging and from other dementias. Severity and length of the illness are other important factors to consider to determine whether the parameters measured also allow identification of stages of the disease.
Studies of platelets also suggest that it may be possible to detect alterations of APP synthesis/metabolism of potential diagnostic significance in sporadic AD patients. In fact, the presence of APP in platelet granules has generated great interest in the study of platelet function and biochemistry in AD patients. Several laboratories have shown that human platelets contain full-length APP (88) (89) (90) (91) (92) (93) and are suitable for the study of APP processing. It has also been proposed that platelets may serve as a possible source of the Ab sequence (93), providing one mechanism by / 381c 0002 Mp 25 Tuesday Nov 25 11:34 AM LP-FASEB 0002 which cerebral amyloid might be derived from the circulation and contribute to cerebral or cerebrovascular amyloidosis. According to Van Nostrand et al. (88) (89) (90) , the protease inhibitor protease nexin-2, the secreted form of APP that contains the Kunitz protease inhibitor domain, may play a role in regulating blood coagulation by inhibiting blood coagulation factor IXa, and platelets may serve as a vehicle to deliver this protein to sites of vascular injury. A recent study (94) has demonstrated the existence of a consistent alteration in platelet APP isoforms in AD and Down's syndrome (i.e., a lower 130-106/110 kDa ratio) that is of potential value as a biochemical marker of the disease.
CSF AND PLASMA. APP, Ab, TAU PROTEIN, AND OTHER MARKER PROTEINS
Amyloid precursor protein or Ab and other APP fragments are detectable in cerebospinal fluid. Lower CSF APP levels in AD patients with respect to controls were demonstrated by several groups (95) (96) (97) (98) . Low sAPP concentrations were also detected by Farlow et al. (97) in CSF from AD patients who carry a point mutation at codon 717 in exon 17 of the APP gene. However, it has not been systematically studied whether the defect is specific to Alzheimer's disease. The concentrations of the soluble extracellular portion of APP (sAPP) are also decreased in AD patients when compared to healthy control subjects (99) and demented non-Alzheimer-type patients (100). Almkvist et al. (101) observed an association between low levels of a-sAPP and poor performance on neuropsychological tests in individuals from a Swedish family with AD and a double mutation at codons 670/ 671 of APP gene.
Seubert et al. (102) first isolated and quantified Ab from human biological fluids (i.e., CSF and plasma). Alterations of CSF Ab levels were reported in AD patients. Nakamura et al. (103) found a significant elevation in the level of Ab in the CSF of early-onset AD patients. On the other hand, Nitsch et al. (104) found that Ab levels in the CSF of AD patients were inversely correlated both to cognitive and functional measures of dementia severity. Lannfelt et al. (105) demonstrated a correlation between decreased soluble Ab levels and duration of illness, but found no differences in CSF levels of Ab between APP670/671 mutation carriers and noncarriers from the Swedish family they studied. Comparable amounts of Ab in AD and control CSF were found by other laboratories (106) (107) (108) , indicating that the total CSF Ab level is not a useful marker for current diagnosis of AD.
Ab CSF levels seem to be a more specific marker of AD pathology than total Ab. In fact, CSF Ab 1-42 levels were significantly lower in AD patients relative to a non-AD group (109) (110) (111) . However, some overlapping of the control Ab 1-42 levels with AD values (109) was present. Ab has recently been shown to deposit in the brain tissue of patients with AD (112, 113) , suggesting that diminished clearance may account for its reduction in AD CSF. The peptide may be elevated early in the disease and decrease during progression (Lannfelt, working group on biological markers of AD, Alzheimer's Association).
Ab concentration also seems to be altered in plasma from AD patients. Song et al. (114) observed that plasma Ab 1-42 is increased in carriers of familial AD linked to chromosome 14. Plasma Ab is also increased in carriers of the 670-671 mutation from the Swedish kindred (115) . No differences in Ab levels were seen between symptomatic and presymptomatic carriers, which shows that the increase of Ab levels might be a very early event in the disease, at least in the Swedish kindred. On the other hand, it cannot be excluded that the increase in Ab levels is unrelated to the pathogenesis of the disease, being indistinctly elevated both in patients and in asymptomatic individuals. Follow-up studies investigating whether the elevated Ab levels in subjects with no symptoms are predictive of a future development of the illness will help to clarify this point. This observation has been interpreted as indicating a potential importance of plasma Ab as an early marker for identifying individuals who will develop AD because of elevated Ab concentrations, at least in cases of FAD. Moreover Younkin et al. (116) observed that an elevated plasma concentration of Ab 1-42 may also play a role in some patients with sporadic AD cases and that, in at least some of these patients, Ab 1-42 may be elevated before the onset of symptoms. This observation has not been replicated by other authors (see below); additional results are clearly needed before drawing any conclusions about the risk for AD that is conferred by elevation of plasma Ab . Scheuner et al. (48) demontrated an increased Ab 1-42 level in plasma from subjects with FAD-linked PS1, PS2, APPK670N, M671L, and APPV717I mutations. Plasma Ab level is also elevated in presymptomatic carriers of PS1 and PS2 mutations. Kosaka et al. (117) found an increased percentage of plasma amyloid ending at Ab42(43) in patients with the bAPP717 mutation. An increased Ab1-40 plasma level was also observed in carriers of the APPK670N, M671L mutation. In contrast, Ab was not statisically increased in subjects with late-onset sporadic AD compared with agematched control subjects. This observation and the finding that Ab was significantly increased in all presymptomatic gene carriers indicate that the increased Ab 1-42 observed in subjects with FAD-linked APP and PS1 or PS2 mutations occurs as a direct consequence of the mutations and not as an indirect manifestation of the AD state. The diagnostic significance of levels of Ab in these cases obviously is 26 Vol. 12 January 1998
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secondary to the finding of the pathogenetic mutation. Tau protein, the main component of neurofibrillary tangles, can also be detected in CSF. Tau levels in the CSF of AD cases are significantly elevated compared to healthy control individuals, vascular dementia patients, and neurological control subjects (118) (119) (120) (121) (122) (123) (124) (125) (126) (127) . It is debated whether tau levels are also elevated in other kinds of neurological diseases where neuronal death or damage occurs. In particular, increased CSF levels of tau are found in a definite proportion (10-20%) of neurological controls (119, 122, 123) . Furthermore, there is an overlap between AD and other forms of dementia, reducing the predictive value of elevated CSF tau. The simultaneous analysis of tau and Ab in the same CSF sample appears to be of particular interest. In fact, the presence of elevated tau levels and reduced Ab 1-42 seems to be highly predictive of AD (specificity 96%). Conversely, high Ab 1-42 and low tau were observed only in control patients (specificity 100%). However, the combined CSF tau and Ab 1-42 measurements were not informative in those patients who fell into the low Ab 1-42 /low tau group. The diagnostic potential of these results needs to be evaluated further (109, 110) .
Among other proteins that are unrelated to the major Alzheimer's markers, such as Ab or tau, the iron binding protein p97 has recently been proposed as a possible diagnostic marker for the disease (128) . Its level has been found to be significantly increased in freshly prepared plasma samples from AD patients. The data are promising because of the virtual absence of overlaps with the levels measured in the plasma of control subjects, including individuals suffering from other neuropathologies. As for many other proposed diagnostic markers for AD, the plasma level of p97 awaits a complete validation on a large number of patients in carefully designed multicenter studies.
NEUROENDOCRINE SYSTEM
The neuropathological hallmarks of Alzheimer's disease are very prominent in the hippocampus (129, 130) , a brain site that is pivotal for regulation of the hypothalamic-pituitary-adrenal (HPA) system. In rats and primates, lesions of the hippocampus result in hypersecretion of glucocorticoid under resting and stress conditions (131) , whereas hippocampal stimulation inhibits this system (132) . There is agreement in the literature about an age-associated reduction in the number of hippocampal corticosteroid receptors, mainly mineralcorticoid receptors, resulting in an age-related increase in HPA system activity (133) (134) (135) .
Studies (136) in healthy elderly humans suggest that with aging, the human HPA system becomes more disinhibited, showing an age-related increase in HPA system activity. Thus, one would expect that, in patients with AD, the age-associated HPA system changes are aggravated by the disease process itself. However, studies of HPA system function in AD patients have so far yielded controversial findings. Hatzinger et al. (137) demonstrated profoundly altered regulation of the HPA system in patients with AD. In fact, they demonstrated that patients with AD had significantly higher basal cortisol concentrations, and a higher percentage of AD patients escaped the dexamethasone (DEX) suppression of cortisol release when compared to elderly controls. On the other hand, the DEX suppression test is typically abnormal in depression, so the observed changes cannot be considered specific for dementia. The alteration of the HPA axis in AD patients is further supported by a significantly lower adrenocorticotropin hormone (ACTH) and cortisol release after administration of additional corticotropin-releasing hormone (CRH), as compared with the control group. In addition, it was demonstrated that CRH and ACTH levels are significantly reduced in the CSF of AD patients (138) (139) (140) in the absence of differences in plasma levels of CRH, ACTH, and cortisol (141) . However, none of the patients showed evidence of pituitary-adrenal dysfunction, suggesting an involvement of extrahypothalamic CRH (138) . Several studies indicate a reduction in CRH-like immunoreactivity in the cerebral cortex of AD patients (142) (143) (144) , particularly in temporal, frontal, and occipital areas. In the same cortical areas, an increased CRH receptor number was reported (142) . Nevertheless, these findings are not specific to Alzheimer's dementia. In fact, reduced levels of CRH in CSF were also demonstrated in patients with vascular dementia (139) (140) (141) , and reduced CRH-like immunoreactivity at the level of the cerebral cortex level was also found in Parkinson's disease and progressive supranuclear palsy (143, 145) . Other alterations in the neuroendocrine system of AD patients have also been reported. An attenuated growth hormone-releasing hormone (GHRH) -induced growth hormone response specific to AD was demonstrated by Lesh et al. (146) and Ghiso et al. (147), but not by others (148, 149) . Furthermore, a reduction in CSF levels of antidiuretic hormone was observed not only in AD patients, but also in patients with frontal lobe dementia (150) . No alteration of the thyrotropin-releasing hormone/thyrotropin hormone (TRH/TSH) and prolactin (PRL) systems was reported in AD patients (151, 152) .
A reduced somatostatin-like immunoreactivity (SLI) in some regions of the AD brain was reported by several groups (153) (154) (155) (156) . However, a reduction is also detectable in the brain of patients with Parkinson's disease (154, 155) or major depression (155) . Also, one report (157) shows an increased SLI in both AD and vascular dementia. Several papers (150, / 381c 0002 Mp 27 Tuesday Nov 25 11:34 AM LP-FASEB 0002 [158] [159] [160] [161] [162] [163] [164] [165] even demonstrated reduced SLI in the CSF of AD patients at early stages of the disease, whereas just one group found no differences between AD and control subjects (165) . However, low SLI values in CSF are not specific to AD; in fact, reduced SLI was demonstrated in the CSF of patients affected not only by neurological disorders such as frontal lobe dementia (150), Parkinson disease (166), vascular dementia, normal pressure hydrocephalus (161, 167) , senile dementia of the Lewy body type (168) , dementia with frontotemporal degeneration (154), and dementia associated with alcoholism (164), but also in psychiatric diseases like major depression (158) and schizophrenia (156) . Therefore, the measurement of SLI in CSF in demented patients may not be helpful in the diagnostic procedure. These observations do not support the existence of a specific neuroendocrine pattern for AD patients. However, the new findings on the relationship between AD and inflammation and estrogens and AD risk in postmenopausal women strongly suggest the need to explore further the potential neuroendocrine alterations in this disease (169) (170) (171) (172) (173) .
APOLIPOPROTEIN E AND DEMENTIA
An important chapter in Alzheimer's disease research regards the role of apolipoprotein E (ApoE) isoforms in the disease. ApoE is a plasma protein involved in cholesterol transport (174) . In the central nervous system, ApoE is produced by astrocytes (175) and is implicated in the growth and repair of the nervous system during development or after injury (176) (177) (178) . ApoE is also increased in several chronic neurodegenerative diseases. In AD, ApoE is bound to extracellular senile plaques, to intracellular neurofibrillary tangles, and at sites of cerebral vessel congophilic angiopathy (179) . Immunoreactivity for ApoE is also detectable in cerebral amyloid deposits and neurofibrillary tangles in kuru and in amyloid plaques of Creutzfeld-Jacob disease (179) .
The ApoE gene is localized on chromosome 19 and presents three alleles-e2, e3, and e4-that determine ApoE polymorphism. Analysis of ApoE alleles in AD and control subjects demonstrated a highly significant association of ApoE type 4 allele (ApoE e4) and late-onset familial Alzheimer's disease (180) . The allele frequency of ApoE e4 in 30 random affected patients, each from a different AD family, was 0.50 { 0.06 vs. a frequency of 0.16 { 0.03 in 91 agematched nonrelated controls. The analysis was then extended to sporadic late-onset AD patients by Saunders et al. (181) : the same kind of association with allele e4 was demonstrated in living and autopsy-documented AD patients vs. controls. The increased frequency of the e4 allele in late-onset sporadic and familial AD was demonstrated in U.S. (180) (181) (182) as well as Japanese, Finnish, and Italian populations (183) (184) (185) (186) (187) . Furthermore, the frequency of the e4 allele also seems to be increased in early onset sporadic AD patients in a Japanese and a Dutch population (188, 189) .
The inheritance of one or two ApoE e4 alleles seems to influence Alzheimer pathology in a gene dose-dependent manner: the amount of histologically identified Ab in vessels and plaques in the cerebral cortex of patients with sporadic late-onset AD is a direct function of their ApoE genotype. Increased amyloid deposits in vessels and increased density of strongly Ab immunoreactive plaques in patients homozygous for ApoE e4 compared with patients homozygous for ApoE e3 have been demonstrated, although the topic is controversial (185) . ApoE e3/e4 patients have an intermediate phenotype (190) . A gene dose effect can also be detected in the age of onset of AD. Inheritance of the ApoE e4 allele is associated with an earlier onset of the disease: the median age at onset among AD patients decreased from 83 to 78 to 74 years as the number of ApoE e4 alleles increased from 0 to 1 to 2, respectively (191) . These findings led to the hypothesis of ApoE e4 as a risk factor for Alzheimer's disease and suggested a potential use of ApoE genotype as a diagnostic test, although the issue is still controversial (192) (193) (194) .
Recently it has been demonstrated that the frequency of ApoE e4 allele is increased not only in AD, but also in other types of dementia. Frisoni et al. (186) confirmed increased ApoE e4 allele frequency in 93 sporadic AD patients, but also demonstrated a similar increase in e4 frequency in 23 vascular dementia patients. Moreover, it has been demonstrated that e4 frequency is also increased in patients affected by Creutzfeld-Jacob disease (195) and by Lewy body dementia (196) , but not in Down's demented subjects (197, 198) .
Therefore, the association of the ApoE e4 allele is not unique to Alzheimer's disease. The use of ApoE genotype as a diagnostic test in symptom-free individuals has insufficient epidemiological support at present to be useful. In fact, it cannot predict when, or if, an individual with ApoE e4/4 will get Alzheimer's disease. On the other hand, the genotype may be used to confirm that patients with early dementia have Alzheimer's disease. ApoE genotyping may also be used to subdivide symptomatic patients by biological risk in order to foresee the response to drug treatment (199) and the clinical progression of the pathology (200) , since the proportion of patients with slow progression seems to increase with increasing e4 gene dose, suggesting that disease duration might be longer in e4 carriers (201) .
In addition to genotyping, several groups have measured ApoE levels in CSF alone or in conjunction with tau and Ab CSF ApoE concentrations in AD patients, irrespective of the ApoE genotype (202) (203) (204) . However, contrasting results have been published; one recent report found no difference (205) in CSF ApoE concentrations, and another found an increase (206) . The decrease of CSF ApoE, on the other hand, does not appear to be limited to AD and, rather, may represent an unspecific marker for neurodegenerative disorders (204) . It is tempting to speculate that since lipoproteins participate in lipid transport during cell repair, the relative lack of ApoE may impair repair mechanisms, making the brain more susceptible to damage. In studies that measured CSF levels of Ab (reduced in AD) or tau (which increases in AD), the two parameters were found to be independent (102, 107) of ApoE genotype. However, in a recent study (207) of a limited number of AD patients followed for 14 months, the ApoE e4 carriers presented increasing tau CSF levels. While this observation awaits confirmation, it may suggest that there are ApoE isoform-specific differences in the regulation of the homeostasis of tau.
CONCLUSION
The use of peripheral tissues and body fluids from AD patients has contributed a considerable amount of evidence toward the evaluation of working pathophysiological hypotheses for this disease, the one depicted in Fig. 2 being an example. According to data reviewed here, a defect in transduction systems might play a key role in the pathogenesis of Alzheimer's disease. For example, the reduced PKC activity observed in AD fibroblasts might influence APP metabolism and reduce APP processing via the nonamyloidogenic pathway with an increased formation of Ab. Many events could follow enhanced Ab production (Ab deposition, facilitation of neurotoxicity, disruption of calcium homeostasis, abnormal tau phosphorylation), resulting in the neurodegenerative pattern and loss of function typical of AD patients. However, this hypothesis needs to be investigated further, and peripheral tissues could be an important tool in the clarification of several other points. The search for a biological marker that could help in predicting or confirming AD diagnosis is still a rich area for research. The attempt to build a biological profile that is characteristic of AD cells, with the association of different variables, seems a more promising approach (87, 110) , at least for sporadic cases. Furthermore, the initial data indicate a need to design studies that are carefully targetted at detecting the diagnostic potential of observed biological differences. A more clinically oriented experimental design, with doubleblind and multicenter tests with preestablished inclusion criteria, should be adopted. 
